Brief: Anavex®2-73 (Blarcamesine) Receives Compassionate Use Authorization For Pediatric Patients With Rett Syndrome
15/06/2023 12:49
June 15 (Reuters) - Anavex Life Sciences Corp AVXL.O :
* ANAVEX®2-73 (BLARCAMESINE) RECEIVES COMPASSIONATE USE
AUTHORIZATION FOR PEDIATRIC PATIENTS WITH RETT SYNDROME
Source text for Eikon: ID:nGNX45sSS0
Further company coverage: AVXL.O
Recent news on Anavex Life Sciences
See all newsBrief: Anavex Provides Corporate Update, Announces Completion Of Clinical Conduct Of Adme And Ddi Clinical Studies
Brief: Anavex Receives FDA Clearance Of Its Ind Application For Blarcamesine In Fragile X Syndrome
Brief: Glass Lewis Recommends Anavex Stockholders To Vote For PVG’s Director Nominees
Brief: PVG Calls For Replacing Anavex Board, Hiring "Experienced" CEO
Brief: Pvg Asset Management- Nominates Six Director Candidates For Anavex Board